UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 APPLICABLE ONLY TO CORPORATE ISSUERS: FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-37606 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its c ...

Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2019 Earnings Conference Call February 7, 2019 4:30 PM ET Company Participants Scott Gordon - IR Christopher Missling - President & CEO Sandra Boenisch - Principal Financial Officer Conference Call Participants Jotin Marango - Roth Capital Ram Selvaraju - H.C. Wainwright Operator Good afternoon my name is Michelle, and I will be your conference call operator for today's call. Welcome to the Anavex Life Sciences Fiscal 2019 First Quarter Financial Results Conferenc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-37606 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 98-0608404 (State or ...